Ignite Creation Date:
2024-05-19 @ 5:34 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06413615
Status:
RECRUITING
Last Update Posted:
2024-05-14
First Post:
2024-05-08
Brief Title:
A Study of FDA022-BB05 in AdvancedMetastatic Solid Tumors
Sponsor:
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Organization:
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Study Overview
Official Title:
A Phase 2 Multicenter Open-Label Study to Assess the Efficacy Safety Tolerability and Pharmacokinetics of FDA022-BB05 in Patients with AdvancedMetastatic Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an open-label multicenter Phase II study to evaluate the efficacy and safety of FDA022-BB05 for the treatment in locally advanced unresectable or metastatic patients with selected HER2 overexpressingexpressing solid tumors which are not eligible for curative therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None